Data Sources
Methods
 Agestandardised rates
 Annual percentage change (APC)
 Australian standard population (2001)
 Conditional survival
 Confidence intervals
 Incidence
 Lifetime risk
 Mortality
 Prevalence
 Survival
Other
Data Sources
Queensland Cancer Register (QCR)
Details of all cancers diagnosed in Queensland are legally required to be included in the QCR under the Public Health Act 2005. Notifications of patients with cancer are received from all public and private hospitals and nursing homes. Queensland pathology laboratories are also required to provide copies of pathology reports for cancer specimens. Information regarding the deaths of persons with cancer is provided to the QCR from the Registrar of Births, Deaths and Marriages.
Basal and Squamous cell skin cancers were not included in the comparisons of cancer types. This is because the basal and squamous cell skin cancers are not registered by the QCR (similar to the practice in most other cancer registries), since many are treated in doctors’ surgeries using techniques that preclude histological confirmation.
Australian Bureau of Statistics (ABS)
Mortality data for all causes of death for Queensland residents were obtained from the Australian Bureau of Statistics. These data were used in relative survival calculations (see Survival). For all years, published and freely available mortality estimates were used [1].
Queensland estimated resident population data used in calculating rates were also obtained from the Australian Bureau of Statistics [2].
Methods
Agestandardised rates
Agestandardised rates attempt to adjust for variation in age structures in different populations (either different geographical areas or the same population across time). There are two methods of agestandardisation – direct and indirect.
All incidence and mortality trends were calculated using directly standardised rates. The method involves applying agespecific rates from the population of interest (i.e. Queensland) to a standard population, which on this website is the Australian Standard Population 2001 [3]. Fiveyear age groups up to 85 years and over were used for all of the agestandardisation.
Annual percentage change (APC)
This is the annual increase or decrease in the incidence or mortality trends over the specified period. Negative APC values describe a decreasing trend and positive APC values describe an increasing trend. A trend is taken to be statistically significant if the 95% confidence interval does not include zero.
APC values were calculated using a statistical method called joinpoint analysis, with software developed by the Statistical Research and Applications Branch of the National Cancer Institute [5]. The joinpoint method evaluates changing trends (both the direction and the magnitude of the trend) over successive segments of time. A joinpoint is the point at which the linear segment changes significantly.
The analysis begins with the assumption of constant change over time (i.e. no joinpoint). Up to four joinpoints were tested in each model, depending on the number of years of data available and the stability of the yearly estimates. The selected trend line was the one with the fewest joinpoints which provided the best fit to the observed data, based on Monte Carlo permutation tests [4].
Australian Standard Population (2001)
The standard population currently used for direct agestandardisation within Australia is the 2001 Australian resident population, which is released by the Australian Bureau of Statistics [3].
Conditional survival
Conditional survival is the probability of surviving an additional y years given the person has already survived x years [5]. It is calculated by dividing the relative survival at (x+y) years after diagnosis by the relative survival at x years after diagnosis, while confidence intervals were calculated using a variation of Greenwood’s formula [6].
Confidence intervals
All estimates are calculated with some degree of uncertainty. This uncertainty is typically reported in terms of a confidence interval, which specifies a range of values in which the true data point is expected to occur with a given level of certainty. For example, a 5year survival rate may be estimated as 11.1% with a 95% confidence interval of 10.3%12.0%. This means that there is a 95% probability that the true survival rate will be somewhere between 10.3% and 12.0%.
Incidence
The incidence of a particular disease is the number of new cases diagnosed in a specified population during a given time period (usually one year). Incidence is also commonly expressed as a rate (e.g. per 100,000 population). Since the risk of most cancers varies with age, it is common practice to agestandardise incidence rates to allow for more valid comparisons between populations (see Agestandardised rates).
Lifetime risk
Cumulative risk is a measure used to estimate the risk of developing or dying of cancer up to the age of 75, 80 or 85, respectively. It takes into account the removal of persons from the population of interest who have already been diagnosed with or died from cancer. Commonly expressed as a ‘1 in n’ proportion, the cumulative risk is calculated as:
where a_{j} are the agespecific rates (5year age groups) per 100,000 for ages 074 (for age 75), 079 (for age 80), or 084 (for age 85).
QCSOL provides the cumulative risk up to the ages of 75, 80 and 85 years as an approximation of lifetime risk. An x in 100 variation is also supplied, calculated as the inverse of the cumulative risk multiplied by 100.
These calculations assume that the person experiences the current agespecific risk rates up to the age specified (e.g. 85), so do not account for any specific risk factors (such as smoking).
Mortality
Mortality measures the number of deaths caused by a given condition within a specified population over a defined time period (usually one year). Similar to incidence, mortality can also be expressed as a rate (per 100,000 population), and these rates are often agestandardised to account for variation in the age structures of different populations (see Agestandardised rates).
Prevalence
Prevalence represents the number of people who had a diagnosis of cancer in the past and are still alive at a specified point in time. It is impacted by both the number of new cancers (incidence) and the length of time patients survive after being diagnosed. Even though two types of cancer might have similar incidence, if one cancer has low survival rates and another cancer has higher survival rates, then the prevalence of the second cancer will be greater.
This website presents “limited duration” prevalence, which counts cases who remain alive at a given time point (e.g. 31st December 2016) as prevalent when they were diagnosed within a specific time period. Limited duration prevalence estimates are presented for 1, 5, 10, 20 and 30year time periods. Note that persons diagnosed with cancer before 1982 (when the Queensland Cancer Register began operating) are not included in any prevalence estimates.
Survival
Survival time is defined as the length of time between when a person is diagnosed with a disease and when they die. However, since the eventual survival time of everyone diagnosed with cancer is not known (for example they may still be alive), statistical adjustments are required to take into account those unknown or censored survival times.
Relative survival was used to estimate the proportion of people who survived for different lengths of time. Relative survival compares the survival of people who have a particular disease or condition against the expected survival of a comparable group from the general population, taking into account age, sex and year of diagnosis. The method does not require knowledge of the specific cause of death, only knowledge of whether the patient has died. Relative survival is the most commonly presented measure of cancer survival when using data from populationbased cancer registries [7]. Patients who were still alive at 31st December 2016 were considered censored.
Relative survival estimates can be calculated using either the period or cohort methods [8]. Relative survival estimates shown were produced using the period approach, which is recognised as providing more uptodate survival estimates [9].
The STATA strs command was used to generate the relative survival estimates [10]. This uses a life table (or actuarial) method for calculating observed survival. This approach involves dividing the total period of observation into a series of discrete time intervals. The survival probabilities were then calculated for each of these intervals, and these were multiplied together to get the estimate for observed survival. Expected survival (based on total Queensland mortality data obtained from the Australian Bureau of Statistics) was calculated based on the Ederer II method [11]. Threeyear averages for expected survival were used to minimise the effects of year to year variation. Relative survival was then obtained from the ratio of observed survival to expected survival.
Other
Cancer ICDO3 codes used
All invasive cancers  C00 to C80 (excluding C44 (M805 to M811)) 
Anus & anal canal cancer  C21 
Bladder cancer  C67 
Bone cancer  C40 to C41 
Brain cancer  C70 to C72 
Breast cancer  C50 
Cervical cancer  C53 
Chronic myeloproliferative diseases  M995 to M996 
Colon cancer  C18 
Colorectal cancer  C18 to C20, C218 
Connective tissue & peripheral nerves cancer  C47, C49 
Endocrine glands cancer  C74 to C75 
Eye cancer  C69 
Floor of mouth cancer  C04 
Gallbladder cancer  C23 to C24 
Gum cancer  C03 
Gynaecological cancers  C51 to C58 
Head and neck cancers  C01 to C14, C30 to C32 
Hodgkin lymphoma  M965 to M966 
Kaposi sarcoma  M914 
Kidney cancer  C64 to C66, C68 
Larynx cancer  C32 
Leukaemia  M980 to M994 (excluding M9733/3) 
Lip cancer  C00 
Liver cancer  C22 
Lung cancer  C33 to C34 
Lymphoid leukaemia  M982 to M983 
Lymphoma  M959 to M972 
Melanoma  C44 and C80 (only M872 to M879) 
Mesothelioma  M905 
Myelodysplastic diseases  M998 
Myeloid leukaemia  M984 to M993 
Myeloma  M973 
Nasal cavity cancer  C30 to C31 
Nasopharynx cancer  C11 
NonHodgkin lymphoma  M959, M967 to M972 
Oesophageal cancer  C15 
Other female genital organs cancer  C52, C55, C57 to C58 
Other lip, oral cavity & pharynx cancer  C14 
Other lymphatic cancers  M974 to M976 
Other major salivary glands cancer  C07 to C08 
Other parts of mouth cancer  C05 to C06 
Other skin cancer  C44 (excluding M805 to M811, M872 to M879) 
Other specified leukaemia  M994 
Ovarian cancer  C56 
Pancreatic cancer  C25 
Penile cancer  C60, C63 
Prostate cancer  C61 
Pyriform sinus & hypopharynx cancer  C12 to C13 
Rectosigmoid junction & rectal cancer  C19 to C20 
Retroperitoneum & peritoneum cancer  C48 
Small intestine cancer  C17 
Stomach cancer  C16 
Testicular cancer  C62 
Thymus, heart, mediastinum & pleura cancer  C37 to C38 
Thyroid cancer  C73 
Tongue cancer  C01 to C02 
Tonsil & oropharynx cancer  C09 to C10 
Unknown primary site cancers  C26, C39, C76 to C77, C80 
Unspecified leukaemia  M980 
Uterine cancer  C54 
Vulva cancer  C51 
In 2007 an alternate method of classifying bladder cancers as invasive or insitu was adopted. This new method is consistent with other Australian Registries, and is based on the layer of the bladder involved. This has resulted in a decreased number of invasive bladder cancers, and only affects data from 2007 onwards. However, the bladder cancer ICDO3 codes have not changed.
References

 Australian Bureau of Statistics, 2018. Deaths, Australia 2017. ABS.Stat Dataset: Deaths, Year of occurrence, Age at death, Agespecific death rates, Sex, States, Territories and Australia. ABS Cat. No. 3302.0. ABS: Canberra. Retrieved 5 October 2018, from http://stat.data.abs.gov.au/Index.aspx?Queryid=457.
 Australian Bureau of Statistics, 2018. Australian Demographic Statistics, Mar 2018. Table 53 Estimated Resident Population by single year of age, Queensland. ABS Cat. No. 3101.0. ABS: Canberra. Retrieved 5 October 2018, from http://www.ausstats.abs.gov.au/ausstats.
 Australian Bureau of Statistics, 2003. Population by age and sex – 2001 census edition. ABS Cat. No. 3201.0. ABS: Canberra. Retrieved 23 July 2007, from http://www.ausstats.abs.gov.au/ausstats.
 National Cancer Institute, 2014. Joinpoint Regression Program, Version 4.1.1. Retrieved 16 September 2014, from http://surveillance.cancer.gov/joinpoint/.
 Baade PD, Youlden DR, Chambers SK, 2011. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust, 194(2):7377.
 Skuladottir H, Olsen JH, 2003. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol, 21(16):30353040.
 Dickman PW, Sloggett A, Hills M, et al., 2004. Regression models for relative survival. Statistics in Medicine, 23(1):5164.
 Brenner H, 2002. Longterm survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet, 360(9340):11311135.
 Brenner H, Gefeller O, Hakulinen T, 2004. Period analysis for ‘uptodate’ cancer survival data: theory, empirical evaluation, computation realisation and applications. European Journal of Cancer, 40:326335.
 Dickman PW, 2004. Estimating and modelling relative survival using Stata. Retrieved 25 Nov 2016, from http://www.pauldickman.com/rsmodel/stata_colon/.
 Ederer F, Axtell LM, Cutler SJ, 1961. The relative survival rate: a statistical methodology. National Cancer Institute Monographs, 6:101121.